Cascadian Therapeutics, Inc. (NASDAQ:CASC) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.

A number of other research analysts have also recently weighed in on the stock. Cowen and Company reissued a “buy” rating on shares of Cascadian Therapeutics in a research note on Tuesday, May 9th. Zacks Investment Research cut shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price objective on shares of Cascadian Therapeutics in a research note on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $6.17.

Shares of Cascadian Therapeutics (NASDAQ:CASC) traded down 0.28% on Friday, hitting $3.61. The stock had a trading volume of 334,501 shares. The stock’s market cap is $182.50 million. Cascadian Therapeutics has a one year low of $3.18 and a one year high of $10.98. The company’s 50 day moving average is $3.83 and its 200 day moving average is $3.96.

Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.06. During the same quarter in the previous year, the firm earned ($1.57) EPS. Equities research analysts predict that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/01/cascadian-therapeutics-inc-casc-downgraded-to-strong-sell-at-valuengine.html.

A number of hedge funds have recently made changes to their positions in CASC. State of Wisconsin Investment Board purchased a new stake in shares of Cascadian Therapeutics during the second quarter worth about $104,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Cascadian Therapeutics during the first quarter worth about $122,000. New York State Common Retirement Fund purchased a new stake in shares of Cascadian Therapeutics during the second quarter worth about $136,000. Citadel Advisors LLC purchased a new stake in shares of Cascadian Therapeutics during the first quarter worth about $142,000. Finally, Rhumbline Advisers purchased a new stake in shares of Cascadian Therapeutics during the second quarter worth about $143,000. Hedge funds and other institutional investors own 82.55% of the company’s stock.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.